Registry to Study Factors That May Impact COVID-19 Occurrence and Severity
Clara Health

IQVIA COVID Active Research Experience (CARE) project

Sponsored by Iqvia


There’s so much we still don’t know about COVID-19, like why some of us have mild symptoms or how diet affects our risk. Finding answers to these questions is more urgent than ever. Without having to leave your home, you can be of vital help by taking part in this survey.

Have you, or someone you know, been exposed to the COVID-19 virus or at a high risk of infection? Whether you have been tested or not, sharing your experience will contribute to research that can lead to answers.

About 
COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study type: Observational Estimated Enrollment: 100000 participants Official Title: Registry to Study Factors That May Impact COVID-19 Occurrence and Severity Actual Study Start Date: April 2, 2020 Estimated Study Completion Date: June 1, 2022

Who is this study for?

Who can participate

  • If you may have been exposed, know someone who has been exposed, or are at high risk of infection to COVID-19
  • Currently live in the U.S. or UK
  • Over the age of 18

What should I expect?

Upon consent and enrollment, participants will complete an initial baseline survey reporting their demographics, relevant medical history, symptoms, use of prescription and non-prescription medications (prophylactic and curative) as well as use of supplements (e.g., vitamins, minerals, herbals) and other factors, such as extent of isolation.

Participants are then followed for 3 months:

  • During Month 1, participants will complete a symptom diary to record symptom progression and severity and provide updates on pharmaceutical and non-pharmaceutical interventions twice a week.
  • During Months 2 and 3, follow-up is reduced to twice a month to reduce patient burden and capture longer-term disease progression and treatment.

Have a question?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you’ll be connected to the study team.